ANO1 and laryngotracheoesophageal cleft: Increasing evidence indicated that TMEM16A is also considered as a good target and potential biomarker for the treatment of gliomas (Liu et al., 2014), PDAC (Sauter et al., 2015) and LC (Jia et al., 2015).